Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;24(6):781-94.
doi: 10.1517/13543784.2015.1026963. Epub 2015 Mar 25.

Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

Edward J Kim  1 , Thomas J Semrad, Richard J Bold
Affiliations
Review

Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

Edward J Kim et al. Expert Opin Investig Drugs. 2015 Jun.

Abstract

Introduction: Despite some recent advances in treatment options, pancreatic cancer remains a devastating disease with poor outcomes. In a trend contrary to most malignancies, both incidence and mortality continue to rise due to pancreatic cancer. The majority of patients present with advanced disease and there are no treatment options for this stage that have demonstrated a median survival > 1 year. As the penultimate step prior to Phase III studies involving hundreds of patients, Phase II clinical trials provide an early opportunity to evaluate the efficacy of new treatments that are desperately needed for this disease.

Areas covered: This review covers the results of published Phase II clinical trials in advanced pancreatic adenocarcinoma published within the past 5 years. The treatment results are framed in the context of the current standards of care and the historic challenge of predicting Phase III success from Phase II trial results.

Expert opinion: Promising therapies remain elusive in pancreatic cancer based on recent Phase II clinical trial results. Optimization and standardization of clinical trial design in the Phase II setting, with consistent incorporation of biomarkers, is needed to more accurately identify promising therapies that warrant Phase III evaluation.

Keywords: Phase II; gemcitabine; pancreatic cancer; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2014 Apr 23; - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine. 2013 Oct 31;369(18):1691–703. This phase III study provides evidence for superiority of gemcitabine and nab-paclitaxel over gemcitabine alone and provides a benchmark for comparing survival and response achieved with new therapy options. - PMC - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of U, Intergroup P. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011 May 12;364(19):1817–25. This phase III study provides evidence for superiority of the FOLFIRINOX regimen over gemcitabine alone and again provides a benchmark for comparing new regimens. - PubMed
    1. Hoeg RT, Lee JA, Mathiason MA, Rokkones K, Serck SL, Crampton KL, Emmel AE, Severson EA, Go RS. Publication outcomes of phase II oncology clinical trials. American journal of clinical oncology. 2009 Jun;32(3):253–7. - PubMed
    1. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1997 Jun;15(6):2403–13. - PubMed

MeSH terms